Mito-Extra (Mitomycin)

Mitomycin, the active ingredient in Mito-Extra, is an antineoplastic (alkylating agent) presented as a sterile solution for intravesical use. It treats non‑muscle invasive bladder cancer in patients whose disease is confined to the bladder lining.

GNH USA supplies Mito-Extra as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Mitomycin is used as a local chemotherapeutic agent for urothelial malignancies.

Non‑muscle invasive bladder cancer: reduces tumour recurrence and progression after transurethral resection. Bladder carcinoma in situ: provides direct cytotoxic effect to eradicate residual malignant cells. Superficial bladder cancer: helps prevent new tumor development following endoscopic surgery.

Mitomycin administered intravesically can cause both local and systemic adverse reactions.

Common Side Effects: - Bladder irritation or burning sensation during or after instillation. - Dysuria and increased urinary frequency. - Hematuria or mild blood in urine. - Nausea or mild gastrointestinal upset. - Transient fatigue or weakness. - Mild systemic absorption leading to low‑grade myelosuppression.

Serious or Rare Side Effects: - Severe chemical cystitis with intense pain and ulceration. - Bladder perforation during instillation. - Significant bone‑marrow suppression causing neutropenia or thrombocytopenia. - Systemic allergic or anaphylactic reactions. - Renal toxicity or acute kidney injury. - Secondary malignancies with long‑term exposure.

Before using Mitomycin intravesically, clinicians should observe several safety measures.

Dose individualized by prescriber: follow the specific regimen ordered for each patient. Renal function monitoring: assess serum creatinine and eGFR before each cycle. Hematologic surveillance: perform complete blood counts to detect myelosuppression. Avoid in active urinary infection: treat infection prior to instillation. Pregnancy and lactation: safety unknown; avoid use in pregnant or breastfeeding patients. Store at room temperature: keep in original container, protect from moisture and light.

Mitomycin may interact with other agents that affect the bladder or systemic toxicity.

Major Interactions (Avoid): - Concomitant intravesical alkylating agents: additive bladder toxicity. - Systemic chemotherapy with myelosuppressive drugs: heightened bone‑marrow suppression. - Nephrotoxic medications (e.g., aminoglycosides): increased risk of renal injury. - Pelvic radiotherapy performed concurrently: amplified urothelial damage. - Live vaccines if systemic absorption occurs: risk of infection.

Moderate Interactions (Monitor Closely): - CYP450 substrates metabolized hepatically: possible altered plasma levels. - Anticoagulants (warfarin, DOACs): monitor for bleeding due to mucosal irritation. - NSAIDs: watch renal function and urinary irritation. - Diuretics: may affect bladder concentration of drug. - ACE inhibitors or ARBs: monitor renal parameters during therapy.